BRPI0716765A2 - mÉtodos e composiÇÕes para administrar agentes hipoglicÊmicos de longa duraÇço - Google Patents

mÉtodos e composiÇÕes para administrar agentes hipoglicÊmicos de longa duraÇço

Info

Publication number
BRPI0716765A2
BRPI0716765A2 BRPI0716765-2A2A BRPI0716765A BRPI0716765A2 BR PI0716765 A2 BRPI0716765 A2 BR PI0716765A2 BR PI0716765 A BRPI0716765 A BR PI0716765A BR PI0716765 A2 BRPI0716765 A2 BR PI0716765A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
long term
hypoglycemic agents
administering long
Prior art date
Application number
BRPI0716765-2A2A
Other languages
English (en)
Inventor
Mark A Bush
Jessica E Matthews
Susan E Walker
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BRPI0716765A2 publication Critical patent/BRPI0716765A2/pt
Publication of BRPI0716765A8 publication Critical patent/BRPI0716765A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0716765A 2006-09-13 2007-09-12 Métodos e composições para administrar agentes hipoglicêmicos de longa duração BRPI0716765A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82547206P 2006-09-13 2006-09-13
US86839106P 2006-12-04 2006-12-04
PCT/US2007/078226 WO2008033888A2 (en) 2006-09-13 2007-09-12 Methods for administering long-lasting hypoglycemic agents

Publications (2)

Publication Number Publication Date
BRPI0716765A2 true BRPI0716765A2 (pt) 2013-09-24
BRPI0716765A8 BRPI0716765A8 (pt) 2017-02-21

Family

ID=39184534

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716765A BRPI0716765A8 (pt) 2006-09-13 2007-09-12 Métodos e composições para administrar agentes hipoglicêmicos de longa duração

Country Status (25)

Country Link
US (3) US8338369B2 (pt)
EP (1) EP2073834B1 (pt)
JP (2) JP5524620B2 (pt)
KR (1) KR101472601B1 (pt)
CN (1) CN103705911A (pt)
AR (1) AR062775A1 (pt)
AU (1) AU2007296499C1 (pt)
BR (1) BRPI0716765A8 (pt)
CA (1) CA2662622C (pt)
CL (1) CL2007002634A1 (pt)
CR (1) CR10684A (pt)
EA (1) EA017159B1 (pt)
ES (1) ES2442869T3 (pt)
IL (1) IL197448A (pt)
JO (1) JO2945B1 (pt)
MA (1) MA30768B1 (pt)
MX (1) MX2009002863A (pt)
MY (1) MY149911A (pt)
NO (1) NO20091266L (pt)
NZ (1) NZ575419A (pt)
PE (2) PE20121528A1 (pt)
SG (2) SG174770A1 (pt)
TW (1) TWI430806B (pt)
WO (1) WO2008033888A2 (pt)
ZA (1) ZA200901548B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1965823T1 (sl) 2005-11-04 2016-09-30 Glaxosmithkline Llc Corporation Service Company Postopki za dajanje hipoglikemičnih sredstev
WO2010068735A1 (en) * 2008-12-10 2010-06-17 Glaxosmithkline Llc. Pharmaceutical compositions
WO2011140176A1 (en) * 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
HUE031405T2 (en) 2011-04-12 2017-07-28 Novo Nordisk As Double-acylated GLP-1 derivatives
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
US20160067184A1 (en) * 2013-05-02 2016-03-10 Novo Nordisk A/S Oral Dosing of GLP-1 Compounds
HRP20212014T1 (hr) 2013-05-28 2022-04-01 Takeda Pharmaceutical Company Limited Spoj peptida
JP6995042B2 (ja) 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
AR125086A1 (es) * 2021-03-23 2023-06-07 Lilly Co Eli Composiciones que contienen análogos de incretina y usos de estas

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69739172D1 (de) * 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
AU764371B2 (en) * 1998-08-28 2003-08-14 Eli Lilly And Company Method for administering insulinotropic peptides
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002046227A2 (en) * 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
MXPA03005135A (es) * 2000-12-13 2003-12-04 Lilly Co Eli Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
AU2002308706A1 (en) * 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
JP4227894B2 (ja) * 2001-08-23 2009-02-18 イーライ リリー アンド カンパニー グルカゴン様ペプチド１アナログ
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
MXPA04003553A (es) 2001-10-18 2004-07-22 Bristol Myers Squibb Co Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas.
EP1997829A1 (en) * 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
CA2484556A1 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1585959A4 (en) * 2002-01-08 2007-11-14 Lilly Co Eli PEPTIDE-1 ANALOGUES OF EXTENSION GLUCAGON TYPE
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
NZ547752A (en) * 2003-11-12 2009-12-24 Phenomix Corp Heterocyclic boronic acid compounds for inhibiting dipeptidyl peptidase-IV
EP1704998B1 (en) * 2004-01-13 2011-04-20 Asahi Glass Company, Limited Multilayer laminate
HUE027902T2 (en) * 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
SI1965823T1 (sl) * 2005-11-04 2016-09-30 Glaxosmithkline Llc Corporation Service Company Postopki za dajanje hipoglikemičnih sredstev
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators

Also Published As

Publication number Publication date
JP2014148524A (ja) 2014-08-21
BRPI0716765A8 (pt) 2017-02-21
PE20080840A1 (es) 2008-08-27
KR101472601B1 (ko) 2014-12-15
EA017159B1 (ru) 2012-10-30
SG10201501749WA (en) 2015-05-28
CN103705911A (zh) 2014-04-09
CR10684A (es) 2009-04-28
EP2073834B1 (en) 2013-10-23
AU2007296499C1 (en) 2013-09-12
ES2442869T3 (es) 2014-02-14
ZA200901548B (en) 2010-02-24
US20130005652A1 (en) 2013-01-03
NZ575419A (en) 2011-11-25
JP2010503697A (ja) 2010-02-04
TWI430806B (zh) 2014-03-21
EP2073834A4 (en) 2010-11-03
KR20090059155A (ko) 2009-06-10
US20100009910A1 (en) 2010-01-14
JO2945B1 (en) 2016-03-15
MX2009002863A (es) 2009-03-30
JP5524620B2 (ja) 2014-06-18
WO2008033888A2 (en) 2008-03-20
IL197448A0 (en) 2011-08-01
EP2073834A2 (en) 2009-07-01
US8338369B2 (en) 2012-12-25
MA30768B1 (fr) 2009-10-01
PE20121528A1 (es) 2012-12-12
JP5753924B2 (ja) 2015-07-22
IL197448A (en) 2013-06-27
EA200970274A1 (ru) 2009-08-28
CA2662622A1 (en) 2008-03-20
CA2662622C (en) 2017-01-17
SG174770A1 (en) 2011-10-28
WO2008033888A3 (en) 2008-10-16
TW200824706A (en) 2008-06-16
AR062775A1 (es) 2008-12-03
AU2007296499B2 (en) 2013-05-02
AU2007296499A1 (en) 2008-03-20
CL2007002634A1 (es) 2008-05-16
NO20091266L (no) 2009-06-09
MY149911A (en) 2013-10-31
US20140066371A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
BRPI0716765A2 (pt) mÉtodos e composiÇÕes para administrar agentes hipoglicÊmicos de longa duraÇço
LTPA2016032I1 (lt) Hipoglikeminių agentų skyrimo būdai
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0812562A2 (pt) composições terapêuticas anti-cd20 e métodos
EP2124556A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0715712A2 (pt) Composição farmacêutica
BRPI0716354A2 (pt) "composiÇço e mÉtodo"
AR062844A1 (es) Composicion pesticida
BRPI0718118A2 (pt) composições e métodos para ligação de sphingosine-1-fosfato
DK2068886T3 (da) Lipidholdige præparater
HUE053515T2 (hu) Szinergetikus prebiotikus készítmények
BRPI0719393A2 (pt) Composição farmacêutica
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
PT2868315T (pt) Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
BRPI0720234A2 (pt) Composição farmacêutica
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0807220B1 (pt) composição, e, métodos para aumentar a força de compressão de uma composição e para aumentar a retenção de fragrância de uma composição
DK1929865T3 (da) Cyclopropensammensætninger
BRPI0903914A2 (pt) Uso de um composto, método para analisar a eficácia de uma composição de liberação prolongada, e, composição farmacêutica.
BRPI0718035A2 (pt) Método e disposição para fabricação de metanol
BRPI0812000A2 (pt) Métodos e composições para administração de oxibutinina
BRPI0912074A2 (pt) composto e composição farmacêutica
EP1980237A4 (en) GELLING
EP2101736A4 (en) HOMOGENEOUS PULP AND GEL PREPARATIONS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: GLAXOSMITHKLINE LLC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL